menu
    • menu

    Company profile for Ensysce Biosciences

    NEW Drugs in Dev: 4
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Ensysce intends to launch the first new class of Opioid analgesics in decades —limiting the chances for abuse while alleviating pain. We’re a biotech company committed to stemming the prescription drug abuse epidemic. Our proprietary prodrug technologies: abuse resistant TAAP™ and overdose resistant MPAR™ are designed to improve the care of patients with chronic pain while reducing the human and economic costs ass...
    Ensysce intends to launch the first new class of Opioid analgesics in decades —limiting the chances for abuse while alleviating pain. We’re a biotech company committed to stemming the prescription drug abuse epidemic. Our proprietary prodrug technologies: abuse resistant TAAP™ and overdose resistant MPAR™ are designed to improve the care of patients with chronic pain while reducing the human and economic costs associated with prescription drug abuse.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Ensysce BiosciencesUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    3210 Merryfield Row San Diego, CA 92121
    Telephone
    Telephone
    (858) 242-1553
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://ensysce.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    PBP World Meeting

    Not Confirmed

    envelop Contact Supplier

    PBP World Meeting

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ensysce Biosciences Launches Live (AMA) Showcasing Growth
    Ensysce Biosciences Launches Live (AMA) Showcasing Growth

    04 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-04/ensysce-biosciences-initiates-live-ask-me-anything-ama-session-highlighting-growth-and-future-pl

    PHARMIWEB
    04 Mar 2026
    Share Share
    Ensysce Biosciences Announces First MPAR Publication
    Ensysce Biosciences Announces First MPAR Publication

    03 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-03/ensysce-biosciences-announces-first-peer-reviewed-clinical-publication-demonstrating-oral-overdose-p

    PHARMIWEB
    03 Mar 2026
    Share Share
    Ensysce Bio Begins Strategic Review To Boost Shareholder Value
    Ensysce Bio Begins Strategic Review To Boost Shareholder Value

    25 Feb 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-02-25/ensysce-biosciences-initiates-review-of-strategic-alternatives-to-enhance-shareholder-value

    PHARMIWEB
    25 Feb 2026
    Share Share
    Ensysce Biosciences Invited to Upcoming Scientific, Industry
    Ensysce Biosciences Invited to Upcoming Scientific, Industry

    23 Feb 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-02-23/ensysce-biosciences-invited-to-participate-in-upcoming-scientific-and-industry-events

    PHARMIWEB
    23 Feb 2026
    Share Share
    Ensysce Biosciences Updates PF614 Phase 3 Enrollment
    Ensysce Biosciences Updates PF614 Phase 3 Enrollment

    28 Jan 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-01-28/ensysce-biosciences-provides-enrollment-update-on-pivotal-phase-3-trial-of-pf614-its-next-generatio

    PHARMIWEB
    28 Jan 2026
    Share Share
    Ensysce Biosciences Issues Annual Shareholder Letter
    Ensysce Biosciences Issues Annual Shareholder Letter

    05 Jan 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-01-05/ensysce-biosciences-issues-annual-shareholder-letter

    PHARMIWEB
    05 Jan 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search